Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and/or heartburn
Zepbound carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
These research areas remain under investigation and require additional controlled studies to better understand the biological mechanisms involved
Ongoing evaluation of self-care skills is crucial for older adults with diabetes, particularly those experiencing sensory or cognitive decline
Abstract Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated complications